









Markets
/
Stocks
/
nasdaq-nlsp
/

NLS Pharmaceutics AG

NLSP



View Detailed Chart

0.762USD

0.000

Close 11/04, 16:00（ET）Quotes delayed by 15 min

3.16MMarket Cap

--P/E TTM



NLS Pharmaceutics AG

0.762

0.000

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

0.00%

5 Days

-27.43%

1 Month

-61.80%

6 Months

-51.77%

Year to Date

-63.89%

1 Year

-82.64%

View Detailed Chart

TradingKey Stock Score of NLS Pharmaceutics AG

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NLS Pharmaceutics AG's Score

Industry at a Glance

Industry Ranking

314 / 501

Overall Ranking

650 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NLS Pharmaceutics AG Highlights

StrengthsRisks

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Overvalued

The company’s latest PE is -0.47, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 223.48K shares, decreasing 36.60% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.